Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Author
- DEMETRI, George D1 ; REICHARDT, Peter2 ; BADALAMENTI, Giuseppe11 ; BLACKSTEIN, Martin12 ; LE CESNE, Axel13 ; SCHÖFFSKI, Patrick14 ; MAKI, Robert G15 ; BAUER, Sebastian16 ; BUI NGUYEN, Binh17 ; JIANMING XU18 ; NISHIDA, Toshirou19 ; CHUNG, John20 ; KANG, Yoon-Koo3 ; KAPPELER, Christian21 ; KUSS, Iris21 ; LAURENT, Dirk21 ; CASALI, Paolo G22 ; BLAY, Jean-Yves4 ; RUTKOWSKI, Piotr5 ; GELDERBLOM, Hans6 ; HOHENBERGER, Peter7 ; LEAHY, Michael8 ; VON MEHREN, Margaret9 ; JOENSUU, Heikki10
[1] Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
[2] Department of Hematology, Oncology, and Palliative Medicine, HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
[3] Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
[4] Léon Bérard Centre and Claude Bernard University, Lyon, France
[5] Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
[6] Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
[7] Division of Surgical Oncology and Thoracic Surgery, University Hospital Mannheim, Mannheim, Germany
[8] The Christie NHS Foundation Trust, Manchester, United Kingdom
[9] Fox Chase Cancer Center, Philadelphia, PA, United States
[10] Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
[11] Department of Oncology, University of Palermo, Palermo, Italy
[12] Medical Oncology Unit, Mount Sinai Hospital, Toronto, ON, Canada
[13] Department of Medicine, Gustave Roussy Institute, Paris, France
[14] Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
[15] Department of Medicine, Mount Sinai School of Medicine, New York, NY, United States
[16] Sarcoma Center, West German Cancer Center, University of Duisburg-Essen, Essen, Germany
[17] Bergonié Institute, Bordeaux, France
[18] Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China
[19] Department of Surgery, Osaka Police Hospital, Osaka, Japan
[20] Bayer Healthcare Pharmaceuticals, Wayne, NJ, United States
[21] Bayer Pharma AG, Berlin, Germany
[22] Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy - Source
Lancet (British edition). 2013, Vol 381, Num 9863, pp 295-302, 8 p ; ref : 33 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiangiogénique Anticancéreux Echec Efficacité traitement Essai clinique phase III Essai clinique Etude multicentrique Imatinib Inhibiteur enzyme International Médecine Placebo Stade avancé Sunitinib Sécurité Toxicité Tumeur stromale gastro-intestinale Essai randomisé contrôlé Monde Cancer Enzyme Inhibiteur de la tyrosine kinase Inhibiteur multikinase Pathologie de l'appareil digestif Pathologie de l'estomac Pathologie de l'intestin Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Failure Treatment efficiency Phase III trial Clinical trial Multicenter study Imatinib Enzyme inhibitor International Medicine Placebo Advanced stage Sunitinib Safety Toxicity Gastrointestinal stromal tumor Randomized controlled trial World Cancer Enzyme Tyrosine kinase inhibitor Multikinase inhibitor Digestive diseases Gastric disease Intestinal disease Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Fracaso Eficacia tratamiento Ensayo clínico fase III Ensayo clínico Estudio multicéntrico Imatinib Inhibidor enzima Internacional Medicina Placebo Estadio avanzado Sunitinib Seguridad Toxicidad Tumor estromal gastrointestinal Ensayo aleatorio controlado Mundo Cáncer Enzima Inhibidor tyrosine kinase inhibidor multicinasa Aparato digestivo patología Estómago patología Intestino patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Generalities in medical sciences
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26838323
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(12)61857-1 
https://dx.doi.org/10.1016/S0140-6736(12)61857-1
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61857-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9863\";s:8:\"\u0000*\u0000spage\";s:3:\"295\";s:8:\"\u0000*\u0000epage\";s:3:\"302\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DEMETRI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"George D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:16:\"REICHARDT, Peter\";i:1;s:21:\"BADALAMENTI, Giuseppe\";i:2;s:18:\"BLACKSTEIN, Martin\";i:3;s:14:\"LE CESNE, Axel\";i:4;s:19:\"SCH\u00d6FFSKI, Patrick\";i:5;s:14:\"MAKI, Robert G\";i:6;s:16:\"BAUER, Sebastian\";i:7;s:16:\"BUI NGUYEN, Binh\";i:8;s:11:\"JIANMING XU\";i:9;s:17:\"NISHIDA, Toshirou\";i:10;s:11:\"CHUNG, John\";i:11;s:14:\"KANG, Yoon-Koo\";i:12;s:19:\"KAPPELER, Christian\";i:13;s:10:\"KUSS, Iris\";i:14;s:13:\"LAURENT, Dirk\";i:15;s:15:\"CASALI, Paolo G\";i:16;s:15:\"BLAY, Jean-Yves\";i:17;s:16:\"RUTKOWSKI, Piotr\";i:18;s:16:\"GELDERBLOM, Hans\";i:19;s:18:\"HOHENBERGER, Peter\";i:20;s:14:\"LEAHY, Michael\";i:21;s:20:\"VON MEHREN, Margaret\";i:22;s:15:\"JOENSUU, Heikki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61857-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9863\";s:8:\"\u0000*\u0000spage\";s:3:\"295\";s:8:\"\u0000*\u0000epage\";s:3:\"302\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DEMETRI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"George D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:16:\"REICHARDT, Peter\";i:1;s:21:\"BADALAMENTI, Giuseppe\";i:2;s:18:\"BLACKSTEIN, Martin\";i:3;s:14:\"LE CESNE, Axel\";i:4;s:19:\"SCH\u00d6FFSKI, Patrick\";i:5;s:14:\"MAKI, Robert G\";i:6;s:16:\"BAUER, Sebastian\";i:7;s:16:\"BUI NGUYEN, Binh\";i:8;s:11:\"JIANMING XU\";i:9;s:17:\"NISHIDA, Toshirou\";i:10;s:11:\"CHUNG, John\";i:11;s:14:\"KANG, Yoon-Koo\";i:12;s:19:\"KAPPELER, Christian\";i:13;s:10:\"KUSS, Iris\";i:14;s:13:\"LAURENT, Dirk\";i:15;s:15:\"CASALI, Paolo G\";i:16;s:15:\"BLAY, Jean-Yves\";i:17;s:16:\"RUTKOWSKI, Piotr\";i:18;s:16:\"GELDERBLOM, Hans\";i:19;s:18:\"HOHENBERGER, Peter\";i:20;s:14:\"LEAHY, Michael\";i:21;s:20:\"VON MEHREN, Margaret\";i:22;s:15:\"JOENSUU, Heikki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61857-1\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61857-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9863\";s:8:\"\u0000*\u0000spage\";s:3:\"295\";s:8:\"\u0000*\u0000epage\";s:3:\"302\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DEMETRI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"George D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:16:\"REICHARDT, Peter\";i:1;s:21:\"BADALAMENTI, Giuseppe\";i:2;s:18:\"BLACKSTEIN, Martin\";i:3;s:14:\"LE CESNE, Axel\";i:4;s:19:\"SCH\u00d6FFSKI, Patrick\";i:5;s:14:\"MAKI, Robert G\";i:6;s:16:\"BAUER, Sebastian\";i:7;s:16:\"BUI NGUYEN, Binh\";i:8;s:11:\"JIANMING XU\";i:9;s:17:\"NISHIDA, Toshirou\";i:10;s:11:\"CHUNG, John\";i:11;s:14:\"KANG, Yoon-Koo\";i:12;s:19:\"KAPPELER, Christian\";i:13;s:10:\"KUSS, Iris\";i:14;s:13:\"LAURENT, Dirk\";i:15;s:15:\"CASALI, Paolo G\";i:16;s:15:\"BLAY, Jean-Yves\";i:17;s:16:\"RUTKOWSKI, Piotr\";i:18;s:16:\"GELDERBLOM, Hans\";i:19;s:18:\"HOHENBERGER, Peter\";i:20;s:14:\"LEAHY, Michael\";i:21;s:20:\"VON MEHREN, Margaret\";i:22;s:15:\"JOENSUU, Heikki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61857-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9863\";s:8:\"\u0000*\u0000spage\";s:3:\"295\";s:8:\"\u0000*\u0000epage\";s:3:\"302\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DEMETRI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"George D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:16:\"REICHARDT, Peter\";i:1;s:21:\"BADALAMENTI, Giuseppe\";i:2;s:18:\"BLACKSTEIN, Martin\";i:3;s:14:\"LE CESNE, Axel\";i:4;s:19:\"SCH\u00d6FFSKI, Patrick\";i:5;s:14:\"MAKI, Robert G\";i:6;s:16:\"BAUER, Sebastian\";i:7;s:16:\"BUI NGUYEN, Binh\";i:8;s:11:\"JIANMING XU\";i:9;s:17:\"NISHIDA, Toshirou\";i:10;s:11:\"CHUNG, John\";i:11;s:14:\"KANG, Yoon-Koo\";i:12;s:19:\"KAPPELER, Christian\";i:13;s:10:\"KUSS, Iris\";i:14;s:13:\"LAURENT, Dirk\";i:15;s:15:\"CASALI, Paolo G\";i:16;s:15:\"BLAY, Jean-Yves\";i:17;s:16:\"RUTKOWSKI, Piotr\";i:18;s:16:\"GELDERBLOM, Hans\";i:19;s:18:\"HOHENBERGER, Peter\";i:20;s:14:\"LEAHY, Michael\";i:21;s:20:\"VON MEHREN, Margaret\";i:22;s:15:\"JOENSUU, Heikki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61857-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9863\";s:8:\"\u0000*\u0000spage\";s:3:\"295\";s:8:\"\u0000*\u0000epage\";s:3:\"302\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DEMETRI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"George D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:16:\"REICHARDT, Peter\";i:1;s:21:\"BADALAMENTI, Giuseppe\";i:2;s:18:\"BLACKSTEIN, Martin\";i:3;s:14:\"LE CESNE, Axel\";i:4;s:19:\"SCH\u00d6FFSKI, Patrick\";i:5;s:14:\"MAKI, Robert G\";i:6;s:16:\"BAUER, Sebastian\";i:7;s:16:\"BUI NGUYEN, Binh\";i:8;s:11:\"JIANMING XU\";i:9;s:17:\"NISHIDA, Toshirou\";i:10;s:11:\"CHUNG, John\";i:11;s:14:\"KANG, Yoon-Koo\";i:12;s:19:\"KAPPELER, Christian\";i:13;s:10:\"KUSS, Iris\";i:14;s:13:\"LAURENT, Dirk\";i:15;s:15:\"CASALI, Paolo G\";i:16;s:15:\"BLAY, Jean-Yves\";i:17;s:16:\"RUTKOWSKI, Piotr\";i:18;s:16:\"GELDERBLOM, Hans\";i:19;s:18:\"HOHENBERGER, Peter\";i:20;s:14:\"LEAHY, Michael\";i:21;s:20:\"VON MEHREN, Margaret\";i:22;s:15:\"JOENSUU, Heikki\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
